Diclofenac/eperisoneAlternative Names: Eperisone/diclofenac; Eprisan D SR
Latest Information Update: 25 Feb 2016
At a glance
- Originator Eisai Co Ltd
- Class Muscle relaxants; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Piperidines; Propiophenones; Small molecules
- Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Back pain
Most Recent Events
- 30 Sep 2011 Eisai completes a phase III trial in Back pain in India (NCT01300312; CTRI/2010/091/002934)
- 28 Feb 2011 Phase-III clinical trials in Back pain in India (PO)